Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
CORT's Cash-to-Debt is ranked higher than
97% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. CORT: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CORT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.72  Med: 611.26 Max: No Debt
Current: No Debt
0.72
No Debt
Equity-to-Asset 0.87
CORT's Equity-to-Asset is ranked higher than
85% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CORT: 0.87 )
Ranked among companies with meaningful Equity-to-Asset only.
CORT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.1  Med: 0.64 Max: 0.89
Current: 0.87
-0.1
0.89
Piotroski F-Score: 7
Altman Z-Score: 24.28
Beneish M-Score: -0.93
WACC vs ROIC
20.83%
211.63%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 36.30
CORT's Operating Margin % is ranked higher than
94% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. CORT: 36.30 )
Ranked among companies with meaningful Operating Margin % only.
CORT' s Operating Margin % Range Over the Past 10 Years
Min: -69827.59  Med: -252.34 Max: 33.2
Current: 36.3
-69827.59
33.2
Net Margin % 63.83
CORT's Net Margin % is ranked higher than
97% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. CORT: 63.83 )
Ranked among companies with meaningful Net Margin % only.
CORT' s Net Margin % Range Over the Past 10 Years
Min: -69537.93  Med: -281.23 Max: 81.11
Current: 63.83
-69537.93
81.11
ROE % 76.21
CORT's ROE % is ranked higher than
99% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. CORT: 76.21 )
Ranked among companies with meaningful ROE % only.
CORT' s ROE % Range Over the Past 10 Years
Min: -356.04  Med: -107.29 Max: 111.15
Current: 76.21
-356.04
111.15
ROA % 66.07
CORT's ROA % is ranked higher than
99% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. CORT: 66.07 )
Ranked among companies with meaningful ROA % only.
CORT' s ROA % Range Over the Past 10 Years
Min: -106.94  Med: -60.48 Max: 89.27
Current: 66.07
-106.94
89.27
ROC (Joel Greenblatt) % 4743.05
CORT's ROC (Joel Greenblatt) % is ranked higher than
99% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. CORT: 4743.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CORT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -370585.71  Med: -32364.33 Max: 4880.42
Current: 4743.05
-370585.71
4880.42
3-Year Revenue Growth Rate 69.40
CORT's 3-Year Revenue Growth Rate is ranked higher than
91% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CORT: 69.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CORT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -50 Max: 230.2
Current: 69.4
0
230.2
GuruFocus has detected 2 Warning Signs with Corcept Therapeutics Inc CORT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CORT's 30-Y Financials

Financials (Next Earnings Date: 2019-01-30 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

CORT Guru Trades in Q3 2017

Caxton Associates 10,300 sh (New)
Paul Tudor Jones 34,734 sh (New)
Jim Simons 3,669,755 sh (+36.76%)
Joel Greenblatt 66,450 sh (+11.39%)
Louis Moore Bacon Sold Out
» More
Q4 2017

CORT Guru Trades in Q4 2017

Jim Simons 4,954,500 sh (+35.01%)
Paul Tudor Jones Sold Out
Caxton Associates Sold Out
Joel Greenblatt 17,834 sh (-73.16%)
» More
Q1 2018

CORT Guru Trades in Q1 2018

Paul Tudor Jones 10,364 sh (New)
Joel Greenblatt 20,712 sh (+16.14%)
Jim Simons 4,798,500 sh (-3.15%)
» More
Q2 2018

CORT Guru Trades in Q2 2018

Chuck Royce 747 sh (New)
John Hussman 125,000 sh (New)
Joel Greenblatt 70,021 sh (+238.07%)
Steven Cohen 400,000 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons 4,345,400 sh (-9.44%)
» More
» Details

Insider Trades

Latest Guru Trades with CORT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ARNA, SZSE:002030, NAS:ESPR, NAS:ACAD, NAS:INSM, NAS:ICPT, BOM:539268, XMCE:ALM, NYSE:CBM, NAS:AIMT, SZSE:002287, NAS:GBT, NAS:ENTA, HKSE:06826, XKRX:095700, NAS:MYOK, NAS:DNLI, LSE:GNS, SZSE:002653, NAS:XLRN » details
Traded in other countries:HTD.Germany,
Headquarter Location:USA
Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.

Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.

Top Ranked Articles about Corcept Therapeutics Inc

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
Judge Denies Teva Pharmaceuticals’ Motion to Dismiss Corcept Therapeutics’ Allegations of Patent Infringement
Corcept Therapeutics Receives Orphan Designation for Relacorilant as Treatment for Pancreatic Cancer
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics Announces Positive Relacorilant Data at the 2018 American Society of Clinical Oncology Meeting
Corcept Therapeutics Announces Positive Relacorilant Data at the 2018 American Society of Clinical Oncology Meeting
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2017 Financial Results, Provide Corporate Update, Host Conference Call
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2017 Preliminary Selected Financial Results; Provides 2018 Revenue Guidance
Interactive Brokers Group Set to Join S&P MidCap 400; Alarm.com Holdings and Corcept Therapeutics to Join S&P SmallCap 600

Ratios

vs
industry
vs
history
PE Ratio 10.76
CORT's PE Ratio is ranked higher than
83% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 28.79 vs. CORT: 10.76 )
Ranked among companies with meaningful PE Ratio only.
CORT' s PE Ratio Range Over the Past 10 Years
Min: 9.61  Med: 61.79 Max: 601
Current: 10.76
9.61
601
Forward PE Ratio 11.42
CORT's Forward PE Ratio is ranked higher than
84% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 28.41 vs. CORT: 11.42 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 10.76
CORT's PE Ratio without NRI is ranked higher than
84% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 28.64 vs. CORT: 10.76 )
Ranked among companies with meaningful PE Ratio without NRI only.
CORT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.61  Med: 61.79 Max: 601
Current: 10.76
9.61
601
Price-to-Owner-Earnings 9.39
CORT's Price-to-Owner-Earnings is ranked higher than
86% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 34.35 vs. CORT: 9.39 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CORT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.39  Med: 68.08 Max: 667.78
Current: 9.39
8.39
667.78
PB Ratio 5.82
CORT's PB Ratio is ranked lower than
66% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CORT: 5.82 )
Ranked among companies with meaningful PB Ratio only.
CORT' s PB Ratio Range Over the Past 10 Years
Min: 1.82  Med: 16.09 Max: 86.18
Current: 5.82
1.82
86.18
PS Ratio 6.97
CORT's PS Ratio is ranked higher than
60% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CORT: 6.97 )
Ranked among companies with meaningful PS Ratio only.
CORT' s PS Ratio Range Over the Past 10 Years
Min: 6.23  Med: 33.75 Max: 1990
Current: 6.97
6.23
1990
Price-to-Free-Cash-Flow 13.94
CORT's Price-to-Free-Cash-Flow is ranked higher than
71% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 37.07 vs. CORT: 13.94 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CORT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.45  Med: 48.06 Max: 195.93
Current: 13.94
12.45
195.93
Price-to-Operating-Cash-Flow 13.90
CORT's Price-to-Operating-Cash-Flow is ranked higher than
64% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 29.99 vs. CORT: 13.90 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CORT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 12.41  Med: 47.6 Max: 188.93
Current: 13.9
12.41
188.93
EV-to-EBIT 15.16
CORT's EV-to-EBIT is ranked higher than
56% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. CORT: 15.16 )
Ranked among companies with meaningful EV-to-EBIT only.
CORT' s EV-to-EBIT Range Over the Past 10 Years
Min: -164.1  Med: -4.95 Max: 488.9
Current: 15.16
-164.1
488.9
EV-to-EBITDA 15.12
CORT's EV-to-EBITDA is ranked higher than
52% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. CORT: 15.12 )
Ranked among companies with meaningful EV-to-EBITDA only.
CORT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -171.8  Med: -4.95 Max: 436.4
Current: 15.12
-171.8
436.4
EV-to-Revenue 5.50
CORT's EV-to-Revenue is ranked higher than
68% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. CORT: 5.50 )
Ranked among companies with meaningful EV-to-Revenue only.
CORT' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.4  Med: 28.9 Max: 1373.5
Current: 5.5
5.4
1373.5
Current Ratio 5.58
CORT's Current Ratio is ranked higher than
63% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. CORT: 5.58 )
Ranked among companies with meaningful Current Ratio only.
CORT' s Current Ratio Range Over the Past 10 Years
Min: 1.89  Med: 6.51 Max: 37.77
Current: 5.58
1.89
37.77
Quick Ratio 5.44
CORT's Quick Ratio is ranked higher than
63% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. CORT: 5.44 )
Ranked among companies with meaningful Quick Ratio only.
CORT' s Quick Ratio Range Over the Past 10 Years
Min: 1.81  Med: 6.41 Max: 37.77
Current: 5.44
1.81
37.77
Days Inventory 359.27
CORT's Days Inventory is ranked lower than
88% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. CORT: 359.27 )
Ranked among companies with meaningful Days Inventory only.
CORT' s Days Inventory Range Over the Past 10 Years
Min: 354.58  Med: 431.96 Max: 2487.36
Current: 359.27
354.58
2487.36
Days Sales Outstanding 29.73
CORT's Days Sales Outstanding is ranked higher than
65% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. CORT: 29.73 )
Ranked among companies with meaningful Days Sales Outstanding only.
CORT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 29.73  Med: 45.5 Max: 61.48
Current: 29.73
29.73
61.48
Days Payable 1.00
CORT's Days Payable is ranked higher than
93% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. CORT: 1.00 )
Ranked among companies with meaningful Days Payable only.
CORT' s Days Payable Range Over the Past 10 Years
Min: 1  Med: 830.78 Max: 15257.8
Current: 1
1
15257.8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.20
CORT's 3-Year Average Share Buyback Ratio is ranked higher than
79% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. CORT: -4.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CORT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -61.6  Med: -20.1 Max: -3.2
Current: -4.2
-61.6
-3.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 9.71
CORT's Price-to-Net-Cash is ranked lower than
66% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. CORT: 9.71 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CORT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.5  Med: 6.91 Max: 376
Current: 9.71
2.5
376
Price-to-Net-Current-Asset-Value 8.19
CORT's Price-to-Net-Current-Asset-Value is ranked lower than
63% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. CORT: 8.19 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CORT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.43  Med: 7.53 Max: 93.33
Current: 8.19
2.43
93.33
Price-to-Tangible-Book 5.82
CORT's Price-to-Tangible-Book is ranked lower than
58% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. CORT: 5.82 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CORT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.31  Med: 7.11 Max: 82.35
Current: 5.82
2.31
82.35
Price-to-Intrinsic-Value-Projected-FCF 3.57
CORT's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
66% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 3.12 vs. CORT: 3.57 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CORT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 3.57  Med: 7.65 Max: 18.81
Current: 3.57
3.57
18.81
Price-to-Median-PS-Value 0.20
CORT's Price-to-Median-PS-Value is ranked higher than
93% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. CORT: 0.20 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CORT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2  Med: 0.88 Max: 43
Current: 0.2
0.2
43
Price-to-Graham-Number 1.67
CORT's Price-to-Graham-Number is ranked higher than
64% of the 200 Companies
in the Global Biotechnology industry.

( Industry Median: 2.27 vs. CORT: 1.67 )
Ranked among companies with meaningful Price-to-Graham-Number only.
CORT' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.67  Med: 7.91 Max: 23.74
Current: 1.67
1.67
23.74
Earnings Yield (Greenblatt) % 6.60
CORT's Earnings Yield (Greenblatt) % is ranked higher than
89% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. CORT: 6.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CORT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -110.2  Med: -12.1 Max: 6.8
Current: 6.6
-110.2
6.8

More Statistics

Revenue (TTM) (Mil) $237.70
EPS (TTM) $ 1.21
Beta2.97
Volatility58.08%
52-Week Range $11.21 - 25.96
Shares Outstanding (Mil)115.47

Analyst Estimate

Dec18 Dec19
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) 0.65 1.14
EPS without NRI ($) 0.65 1.14
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}